Chairman
Atara Biotherapeutics, Inc. (ATRA)Equibles does not estimate personal net worth.
Pascal Touchon is recorded as Chairman at Atara Biotherapeutics, Inc. (ATRA) since September 9, 2024. Atara Biotherapeutics, Inc. reported in an 8-K filed September 4, 2025 that Pascal Touchon resigned as director, effective September 2, 2025. Atara Biotherapeutics, Inc. reported in an 8-K filed November 12, 2024 that Pascal Touchon was appointed Chairman of the Board of Directors, effective September 9, 2024. Atara Biotherapeutics, Inc. reported in an 8-K filed August 12, 2024 that Pascal Touchon was appointed Chairman of the Board, effective September 9, 2024. Equibles holds 4 filed executive changes naming Pascal Touchon; each is listed under recent activity with its source filing. The proxy statement of Atara Biotherapeutics, Inc. reports total compensation of $1,722,332 for Pascal Touchon in fiscal 2024, including a base salary of $503,633. Disclosed compensation is on record for 6 fiscal years. Pascal Touchon has spoken on 11 earnings calls across 1 company, most recently for Atara Biotherapeutics, Inc. on November 1, 2023. Atara Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atara Biotherapeutics, Inc. includes AnhCo "Cokey" Thieu Nguyen (CEO), AnhCo Nguyen (CEO and Board Member), Cokey Nguyen (CEO) and 7 others.
“on September 2, 2025, each of Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo, M.D., notified the Board that they will each voluntarily resign from the Board effective as of September 2, 2025 (the "Resignation Effective Date").”
“As previously announced, on September 9, 2024, Cokey Nguyen, Ph.D. became President and CEO and Pascal Touchon assumed the role of Chairman of the Board of Directors”
“Today, we announced the global expansion of our tab-cel partnership with Pierre Fabre Laboratories. We are already successfully launching this product across Europe.”
“We are extremely excited that tab-cel, under the trade name of Ebvallo, received a CHMP positive opinion for its first indication and is on track to obtain European Commission approval by the end of this year.”
“Today, we announced plans to further focus our company's activity as a leaner research and development-centered organization designed to advance our innovative pipeline while, at the same time, reducing future cash burn.”
“I would like to start with ATA188, our potentially transformative therapy for multiple sclerosis, where in the first quarter, we have made good progress and momentum continues to build around this exciting program.”
“In the fourth quarter and in 2021, Atara made important progress in the course of three strategic priorities that center around ATA188 in multiple sclerosis and our next generation allogeneic CAR T programs.”
2024-09-09–present
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Start not stated–2024-09-09
Start not stated–2025-09-02
Biotechnology · Healthcare
Chairman
2024-09-09–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. Former President and Chief Executive Officer | $503,633 | $1,722,332 |
| 2023 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. Former President and Chief Executive Officer | $723,450 | $4,375,125 |
| 2022 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. | $717,938 | $5,158,127 |
| 2021 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. | $680,625 | $5,117,335 |
| 2020 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. | $654,857 | $5,285,827 |
| 2019 | Atara Biotherapeutics, Inc. (ATRA) | D.V.M. President & Chief Executive Officer | $319,327 | $6,637,307 |
